Samsung Looks To Follow Celltrion's Footsteps With Remicade Biosimilar
This article was originally published in PharmAsia News
Executive Summary
Samsung Bioepis’ US 351(k) application relies on data extrapolation from a Phase III trial in rheumatoid arthritis to support approval across infliximab's indications, including inflammatory bowel disease.